Arrowhead Pharmaceuticals, Inc.
ARWR
$65.05
-$0.03-0.04%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 99.73% | 72.45% | 69.42% | -115.53% | -192.04% |
| Total Depreciation and Amortization | 28.68% | 29.48% | 32.68% | 39.10% | 48.84% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 88.79% | 27.62% | 24.84% | 11.95% | 2.78% |
| Change in Net Operating Assets | -172.68% | -63.01% | -34.06% | 1,021.02% | 148.68% |
| Cash from Operations | 138.79% | 106.21% | 123.80% | -150.38% | -200.77% |
| Capital Expenditure | 83.98% | 78.21% | 75.83% | 61.10% | 19.96% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 61.73% | -2,767.47% | -1,806.70% | -228.07% | -445.74% |
| Cash from Investing | 69.22% | -154.94% | -204.79% | -926.28% | -336.87% |
| Total Debt Issued | -97.38% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -43.16% | -43.30% | -43.36% | 15,644.21% | 14,038.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -57.33% | -66.27% | -- | -- | -81.25% |
| Cash from Financing | -91.50% | -4.73% | 27.60% | 32,366.73% | 244.01% |
| Foreign Exchange rate Adjustments | -109.55% | 28,178.57% | 2,205.70% | 6,918.97% | 3,540.16% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,609.42% | 268.06% | 899.52% | 97.00% | -384.34% |